These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

701 related articles for article (PubMed ID: 22515555)

  • 21. Machine learning and artificial intelligence in physiologically based pharmacokinetic modeling.
    Chou WC; Lin Z
    Toxicol Sci; 2023 Jan; 191(1):1-14. PubMed ID: 36156156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repository Describing the Anatomical, Physiological, and Biological Changes in an Obese Population to Inform Physiologically Based Pharmacokinetic Models.
    Berton M; Bettonte S; Stader F; Battegay M; Marzolini C
    Clin Pharmacokinet; 2022 Sep; 61(9):1251-1270. PubMed ID: 35699913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parameters for pyrethroid insecticide QSAR and PBPK/PD models for human risk assessment.
    Knaak JB; Dary CC; Zhang X; Gerlach RW; Tornero-Velez R; Chang DT; Goldsmith R; Blancato JN
    Rev Environ Contam Toxicol; 2012; 219():1-114. PubMed ID: 22610175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and evaluation of a generic physiologically based pharmacokinetic model for children.
    Edginton AN; Schmitt W; Willmann S
    Clin Pharmacokinet; 2006; 45(10):1013-34. PubMed ID: 16984214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Age-Related Pyrethroid Pharmacokinetic Differences in Rats: Physiologically-Based Pharmacokinetic Model Development Using In Vitro Data and In Vitro to In Vivo Extrapolation.
    Song G; Moreau M; Efremenko A; Lake BG; Wu H; Bruckner JV; White CA; Osimitz TG; Creek MR; Hinderliter PM; Clewell HJ; Yoon M
    Toxicol Sci; 2019 Jun; 169(2):365-379. PubMed ID: 30768128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Age-Related Changes in Pediatric Physiology: Quantitative Analysis of Organ Weights and Blood Flows : Age-Related Changes in Pediatric Physiology.
    Chang HP; Kim SJ; Wu D; Shah K; Shah DK
    AAPS J; 2021 Mar; 23(3):50. PubMed ID: 33791883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling interindividual variation in physiological factors used in PBPK models of humans.
    Price PS; Conolly RB; Chaisson CF; Gross EA; Young JS; Mathis ET; Tedder DR
    Crit Rev Toxicol; 2003; 33(5):469-503. PubMed ID: 14594104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.
    Schlender JF; Meyer M; Thelen K; Krauss M; Willmann S; Eissing T; Jaehde U
    Clin Pharmacokinet; 2016 Dec; 55(12):1573-1589. PubMed ID: 27351180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.
    Ghobadi C; Johnson TN; Aarabi M; Almond LM; Allabi AC; Rowland-Yeo K; Jamei M; Rostami-Hodjegan A
    Clin Pharmacokinet; 2011 Dec; 50(12):809-22. PubMed ID: 22087867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
    Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
    Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toxicokinetic modeling and its applications in chemical risk assessment.
    Andersen ME
    Toxicol Lett; 2003 Feb; 138(1-2):9-27. PubMed ID: 12559690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment.
    Andersen ME
    Toxicol Lett; 1995 Sep; 79(1-3):35-44. PubMed ID: 7570672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of physiologically based pharmacokinetic modeling for sertraline dosing recommendations in pregnancy.
    George B; Lumen A; Nguyen C; Wesley B; Wang J; Beitz J; Crentsil V
    NPJ Syst Biol Appl; 2020 Nov; 6(1):36. PubMed ID: 33159093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimization of Drugs Pharmacotherapy During Pregnancy Using Physiologically Based Pharmacokinetic Models - An Update.
    Alsmadi MM; Idkaidek N
    Curr Drug Metab; 2018; 19(12):972-978. PubMed ID: 29962340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physiological parameter values for physiologically based pharmacokinetic models in food-producing animals. Part I: Cattle and swine.
    Lin Z; Li M; Wang YS; Tell LA; Baynes RE; Davis JL; Vickroy TW; Riviere JE
    J Vet Pharmacol Ther; 2020 Sep; 43(5):385-420. PubMed ID: 32270548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incorporating human interindividual biotransformation variance in health risk assessment.
    Lipscomb JC; Kedderis GL
    Sci Total Environ; 2002 Apr; 288(1-2):13-21. PubMed ID: 12013540
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Amaeze O; Isoherranen N; Shum S
    Drug Metab Dispos; 2024 May; ():. PubMed ID: 38811157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A physiologically based pharmacokinetic computer model for human pregnancy.
    Luecke RH; Wosilait WD; Pearce BA; Young JF
    Teratology; 1994 Feb; 49(2):90-103. PubMed ID: 8016750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PBPK models in risk assessment--A focus on chloroprene.
    DeWoskin RS
    Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PBPK Modeling to Simulate the Fate of Compounds in Living Organisms.
    Bois FY; Tebby C; Brochot C
    Methods Mol Biol; 2022; 2425():29-56. PubMed ID: 35188627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.